The consistently poor transparency on NBIOs; the various Offers that have fallen by the wayside (without any basis for doing so), plus an ongoing (and apparently unresolved) litigation, gives pause.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.